Media Pack
News

Current Edition

Volume 16 Issue 1
 
Regional News

As BioNTech raises expected COVID-19 vaccine sales to $19.6B, CEO stumps for wider booster use

Like its partner on its COVID-19 vaccine, BioNTech keeps upping its estimate for 2021 vaccine revenue. Last week, Pfizer jacked up its annual guidance on its vaccine ...
10 November 2021 Regional News BioNTech | COVID-19
Continue Reading →
Regional News

Pfizer’s COVID vaccine for younger kids meets FDA bar, with CDC panel next week being key to wide rollout

Kids ages 5-11 in the United States are now eligible for vaccination against COVID-19. On Friday afternoon, the FDA authorized the Pfizer-BioNTech mRNA vaccine, Comir...
2 November 2021 Regional News clinical trial | COVID-19
Continue Reading →
Regional News

Pfizer’s COVID-19 vaccine is safe, effective in kids ages 5 to 11, setting up possible FDA nod

Amid the nationwide COVID-19 vaccination campaign, youngsters 11 and under have been ineligible for shots—even though millions are back in school. With new Pfizer dat...
26 October 2021 Regional News COVID-19 | FDA
Continue Reading →
Regional News

Johnson & Johnson wins FDA panel backing for a second dose of its COVID shot but don’t call it a ‘booster’

Over the last year, the Johnson & Johnson COVID-19 vaccine has been commonly referred to as a single-shot alternative to the two-dose regimens of mRNA vaccines fr...
20 October 2021 Regional News COVID-19 | FDA
Continue Reading →
Regional News

Pfizer, Moderna will rake in a combined $93 billion next year on COVID-19 vaccine sales

If you think Pfizer-BioNTech and Moderna are making a fortune on COVID-19 vaccine sales this year, just wait for 2022. The messenger RNA shot producers are projected...
20 October 2021 Regional News COVID-19 | COVID-19 vaccine
Continue Reading →
Regional News

FDA delays decision on Moderna’s COVID-19 vaccine in 12-17 age group because of myocarditis concerns

After reports in four Nordic countries of the heart inflammation condition myocarditis, the FDA has delayed a decision on the Moderna COVID-19 shot for kids between t...
20 October 2021 Regional News COVID-19 | FDA
Continue Reading →
Regional News

FDA ready to bless mixing and matching of COVID-19 vaccines as boosters

Data from a National Institutes of Health (NIH) study on booster shots have convinced the FDA to allow Americans to use a different COVID-19 vaccine for a booster dos...
20 October 2021 Regional News booster | COVID-19
Continue Reading →
Volume 13 Issue 5

Operationalising Decentralised Clinical Trials (DCTs)

The Challenges and Change Management Approaches, Considering Trial Designs and Timelines with Decentralisation Methods at the Forefront While components of fully dec...
18 October 2021 Volume 13 Issue 5 clinical trials | COVID-19
Continue Reading →
Volume 13 Issue 5

Plain Language Summaries of Publications – What Has COVID-19 Taught Us?

The COVID-19 pandemic has significantly impacted the whole world and the public has had to struggle with understanding scientific data on a daily basis. The impact of...
18 October 2021 Volume 13 Issue 5 COVID-19 | Language
Continue Reading →
Regional News

Merck and Ridgeback’s molnupiravir will be ‘complementary, but not a competitor’ to COVID-19 vaccines: analyst

What do Merck and Ridgeback’s eye-opening data, recently released for its antiviral molnupiravir on high-risk COVID-19 patients, mean for manufacturers of vaccines? ...
6 October 2021 Regional News antiviral molnupiravir | COVID-19
Continue Reading →
 
 

jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2024, All Rights Reserved – Powered by Teksyte